Optimising Patient Drug Delivery Through Biosimilars and Generics

Biosimilars are typically administered via injection, leading to complications due to the need for devices that mimic those still protected by patents. This results in a limited number of companies capable of providing suitable solutions. Successfully addressing this issue requires navigating a complex intellectual property landscape and securing difficult-to-obtain licenses